The anti-tumor performance of docetaxel liposomes surface-modified with glycyrrhetinic acid

Journal of Drug Targeting

Volumn 20, Issue 5, 2012, Pages 467-473

  Li, Jie ^a   Xu, Haie ^b   Ke, Xue ^a   Tian, Jilai ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Anti tumor; Glycyrrhetinic acid; Hepatocytes target; Liposomes; Surface modification

Indexed keywords

DOCETAXEL; GLYCYRRHETINIC ACID; LIPOSOME; PACLITAXEL;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SIZE; CELL TRANSPORT; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; ENDOCYTOSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER CELL CARCINOMA; MALE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; FEMALE; GLYCYRRHETINIC ACID; HEP G2 CELLS; HEPATOCYTES; HUMANS; LIPOSOMES; LIVER; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PARTICLE SIZE; RATS; RATS, WISTAR; TAXOIDS;

EID: 84861059344     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2012.685475     Document Type: Article

References (23)

1. Cui J, Li C, Guo W, Li Y, Wang C, Zhang L, Zhang L, Hao Y, Wang Y. (2007). Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy? J ControlRelease, 118, 204-215. (Pubitemid 46350710)
2. Gaumet M, Vargas A, Gurny R, Delie F. (2008). Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm, 69, 1-9. (Pubitemid 351467152)
3. He ZY, Zheng X, Wu XH, Song XR, He G, Wu WF, Yu S, Mao SJ, Wei YQ. (2010). Development of glycyrrhetinic acid-modified stealth cationic liposomes for gene delivery. Int J Pharm397, 147-154.
4. Huang G, Diakur J, Xu Z, Wiebe LI. (2008). Asialoglycoprotein receptortargeted superparamagnetic iron oxide nanoparticles. Int J Pharm, 360, 197-203.
5. Huang W, Wang W, Wang P, Tian Q, Zhang C, Wang C, Yuan Z, Liu M, Wan H, Tang H. (2010). Glycyrrhetinic acid-modified poly(ethylene glycol)-b-poly(gamma- benzyl l-glutamate) micelles for livertargeting therapy. Acta Biomater, 6, 3927-3935.
6. Huang W, Wang W, Wang P, Zhang CN, Tian Q, Zhang Y, Wang XH, Cha RT, Wang CH, Yuan Z. (2011). Glycyrrhetinic acid-functionalized degradable micelles as liver-targeted drug carrier. J Mater Sci Mater Med, 22, 853-863.
7. Il'icheva TN, Proniaeva TR, Smetannikov AA, Pokrovskii AG. (1998). [Content of progesterone, glucocorticoid and glycyrrhizic acid receptors in normal and tumoral human breast tissue]. Vopr Onkol, 44, 390-394.
8. Ke X, Wang CJ, Yan F. (2008). Filtration by microspore film fordetermination of the entrapment efficiency of docetaxel liposomes. Chin J Mod Appl Pharm, 25,314-316.
9. Kim Eun-Mi, Jeong Hwan-Jeong, In-Kyu Park, Cho Chong-Su, Moon Hyung-Bae, Yu Dae-Yeul, Bom Hee-Seung, Sohn Myung-Hee, In-Joon Oh. (2005). Asialoglycoprotein receptor targeted gene delivery using galactosylated polyethylenimine-graftpoly( ethylene glycol): In vitro and in vivo studies. J Control Release,108, 557-567. (Pubitemid 41608683)
10. Li J, Ke X. (2011). Preparation of docetaxel liposomes surface-modifiedwith glycyrrhetinic acid and its in vitro anti-tumor effect. Pharm Clin Res, 19, 207-210.
11. Li Y, Huang G, Diakur J, Wiebe LI. (2008). Targeted delivery of macromolecular drugs: asialoglycoprotein receptor (ASGPR) expression by selected hepatoma cell lines used in antiviral drug development. Curr Drug Deliv, 5, 299-302.
12. Lin A, Chen J, Liu Y, Deng S, Wu Z, Huang Y, Ping Q. (2009). Preparation and evaluation of N-caproyl chitosan nanoparticles surface modified with glycyrrhizin for hepatocyte targeting. Drug Dev Ind Pharm, 35, 1348-1355.
13. Mao SJ, Bi YQ, Jin H, Wei DP, He R, Hou SX. (2007). Preparation, characterization and uptake by primary cultured rat hepatocytes ofliposomes surface-modified with glycyrrhetinic acid. Pharmazie, 62, 614-619.
14. Negishi M, Irie A, Nagata N, Ichikawa A. (1991). Specific binding of glycyrrhetinic acid to the rat liver membrane. Biochim Biophys Acta, 1066, 77-82.
15. Spanjer HH, Morselt H, Scherphof GL. (1984). Lactosylceramideinduced stimulation of liposome uptake by Kupffer cells in vivo.Biochim Biophys Acta, 774, 49-55. (Pubitemid 14073211)
16. Stockert RJ, Morell AG. (1983). Hepatic binding protein: the galactosespecific receptor of mammalian hepatocytes. Hepatology, 3,750-757. (Pubitemid 13007704)
17. Tian Q, Wang X, Wang W, Zhang C, Liu Y, Yuan Z. (2010a). Insight intoglycyrrhetinic acid: the role of the hydroxyl group on liver targeting. Int J Pharm, 400, 153-157.
18. Tian Q, Wang W, He XT, Zhu XC, Huang W, Zhang CN, Yuan Z, Chen XS. (2009). Glycyrrhetinic acid-modified nanoparticles for drug delivery: Preparation and characterization. Chin Sci Bull, 54, 3121-3126.
19. Tian Q, Zhang CN, Wang XH, Wang W, Huang W, Cha RT, Wang CH, Yuan Z, Liu M, Wan HY, Tang H. (2010b). Glycyrrhetinic acidmodified chitosan/poly(ethylene glycol) nanoparticles for livertargeted delivery. Biomaterials, 31, 4748-4756.
20. Wu J, Nantz MH, Zern MA. (2002). Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications. Front Biosci, 7, d717-d725.
21. Yang SM, Zhou, FC, Gu YD, Liu ST, Jiang XL,Cheng LZ. (1999). Respective expressions of the receptors for glycyrrhetinic acid and for glycyrrhizin on isolated hepatocyte memberanes. Chin J Hepatol, 7, 27-29.
22. Zhang C, Wang W, Liu T, Wu Y, Guo H, Wang P, Tian Q, Wang Y, Yuan Z. (2012). Doxorubicin-loaded glycyrrhetinic acid-modified alginate nanoparticles for liver tumor chemotherapy. Biomaterials, 33, 2187-2196.
23. Zhu L, Mahato RI. (2010). Targeted delivery of siRNA to hepatocytes and hepatic stellate cells by bioconjugation. Bioconjug Chem, 21, 2119-2127.